Literature DB >> 31759158

Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom Scale.

Christopher Teh1, Lynn Onstad1, Stephanie J Lee2.   

Abstract

Chronic graft-versus-host disease (cGVHD) adversely affects patient quality of life, functional status, and survival after allogenic hematopoietic cell transplantation. The Lee Symptom Scale is a 30-item scale developed to measure the symptoms of cGVHD. Although the original 30-item scale uses a 1-month recall period, we tested the reliability and validity of a 28-item scale (deleting 2 items based on supportive care needs rather than symptoms) with a 7-day recall period, a format that is more appropriate for use in clinical trials. Results show the modified 7-day scale is reliable and valid in the modern era and may be used to assess the symptom burden of cGVHD in clinical trials. Using the distribution method, a 5- to 6-point difference (half a standard deviation) is considered clinically meaningful.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic graft-versus-host disease; patient-reported outcomes; quality of life; survey; symptoms

Mesh:

Year:  2019        PMID: 31759158      PMCID: PMC7031026          DOI: 10.1016/j.bbmt.2019.11.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  14 in total

1.  Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews.

Authors:  Emily C Merkel; Sandra A Mitchell; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-02       Impact factor: 5.742

2.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.

Authors:  Kirsten M Williams; Guang-Shing Cheng; Iskra Pusic; Madan Jagasia; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Jason W Chien; David A Jacobsohn; Steven Z Pavletic; Paul J Martin; Barry E Storer; Yoshihiro Inamoto; Xiaoyu Chai; Mary E D Flowers; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-22       Impact factor: 5.742

3.  Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report.

Authors:  Steven Z Pavletic; Paul Martin; Stephanie J Lee; Sandra Mitchell; David Jacobsohn; Edward W Cowen; Maria L Turner; Gorgun Akpek; Andrew Gilman; George McDonald; Mark Schubert; Ann Berger; Peter Bross; Jason W Chien; Daniel Couriel; J P Dunn; Jane Fall-Dickson; Ann Farrell; Mary E D Flowers; Hildegard Greinix; Steven Hirschfeld; Lynn Gerber; Stella Kim; Robert Knobler; Peter A Lachenbruch; Frederick W Miller; Barbara Mittleman; Esperanza Papadopoulos; Susan K Parsons; Donna Przepiorka; Michael Robinson; Michael Ward; Bryce Reeve; Lisa G Rider; Howard Shulman; Kirk R Schultz; Daniel Weisdorf; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2006-03       Impact factor: 5.742

Review 4.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

5.  Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.

Authors:  Irwin Walker; Tony Panzarella; Stephen Couban; Felix Couture; Gerald Devins; Mohamed Elemary; Geneviève Gallagher; Holly Kerr; John Kuruvilla; Stephanie J Lee; John Moore; Thomas Nevill; Gizelle Popradi; Jean Roy; Kirk R Schultz; David Szwajcer; Cynthia Toze; Ronan Foley
Journal:  Lancet Oncol       Date:  2015-12-24       Impact factor: 41.316

6.  A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

Authors:  Sally Arai; Joseph Pidala; Iskra Pusic; Xiaoyu Chai; Samantha Jaglowski; Nandita Khera; Jeanne Palmer; George L Chen; Madan H Jagasia; Sebastian A Mayer; William A Wood; Michael Green; Teresa S Hyun; Yoshihiro Inamoto; Barry E Storer; David B Miklos; Howard M Shulman; Paul J Martin; Stefanie Sarantopoulos; Stephanie J Lee; Mary E D Flowers
Journal:  Clin Cancer Res       Date:  2015-09-16       Impact factor: 12.531

7.  Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.

Authors:  David Miklos; Corey S Cutler; Mukta Arora; Edmund K Waller; Madan Jagasia; Iskra Pusic; Mary E Flowers; Aaron C Logan; Ryotaro Nakamura; Bruce R Blazar; Yunfeng Li; Stephen Chang; Indu Lal; Jason Dubovsky; Danelle F James; Lori Styles; Samantha Jaglowski
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

8.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.

Authors:  Stephanie k Lee; E Francis Cook; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

Review 9.  Classification systems for chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

10.  Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

Authors:  Stephanie J Lee; Brent Logan; Peter Westervelt; Corey Cutler; Ann Woolfrey; Shakila P Khan; Edmund K Waller; Richard T Maziarz; Juan Wu; Bronwen E Shaw; Dennis Confer; Mary M Horowitz; Claudio Anasetti
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

View more
  6 in total

1.  The safety and tolerability of pirfenidone for bronchiolitis obliterans syndrome after hematopoietic cell transplant (STOP-BOS) trial.

Authors:  Efthymia Iliana Matthaiou; Husham Sharifi; Christian O'Donnell; Wayland Chiu; Clark Owyang; Paulami Chatterjee; Ihsan Turk; Laura Johnston; Theresa Brondstetter; Karen Morris; Guang-Shing Cheng; Joe L Hsu
Journal:  Bone Marrow Transplant       Date:  2022-05-31       Impact factor: 5.174

2.  Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation.

Authors:  Xiaoyu Zhang; Xiaoli Zhao; Yuyan Shen; Yuanyuan Shi; Lining Zhang; Mengze Hao; Fei Zhao; Rongli Zhang; Jialin Wei; Sizhou Feng; Yi He; Erlie Jiang; Mingzhe Han
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

3.  FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy.

Authors:  Robert Q Le; Xin Wang; Hongfei Zhang; Hongshan Li; Donna Przepiorka; Jonathon Vallejo; Ruby Leong; Lian Ma; Kirsten B Goldberg; Richard Pazdur; Marc R Theoret; Angelo De Claro
Journal:  Oncologist       Date:  2022-06-08       Impact factor: 5.837

4.  Impact of Resistance Exercise and Nutritional Endorsement on physical performance in patients with GvHD (IRENE-G study) - design and rational of a randomized controlled trial.

Authors:  Janina Bujan Rivera; Rea Kühl; Ulrike Zech; Anne Hendricks; Thomas Luft; Peter Dreger; Birgit Friedmann-Bette; Theresa-Maria Betz; Joachim Wiskemann
Journal:  BMC Cancer       Date:  2022-04-22       Impact factor: 4.638

5.  Cancer-related impairments and functional limitations among long-term cancer survivors: Gaps and opportunities for clinical practice.

Authors:  Larissa Nekhlyudov; Grace B Campbell; Kathryn H Schmitz; Gabriel A Brooks; Anita J Kumar; Patricia A Ganz; Diane Von Ah
Journal:  Cancer       Date:  2021-09-16       Impact factor: 6.921

6.  Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.

Authors:  Corey Cutler; Stephanie J Lee; Sally Arai; Marcello Rotta; Behyar Zoghi; Aleksandr Lazaryan; Aravind Ramakrishnan; Zachariah DeFilipp; Amandeep Salhotra; Wanxing Chai-Ho; Rohtesh Mehta; Trent Wang; Mukta Arora; Iskra Pusic; Ayman Saad; Nirav N Shah; Sunil Abhyankar; Carlos Bachier; John Galvin; Annie Im; Amelia Langston; Jane Liesveld; Mark Juckett; Aaron Logan; Levanto Schachter; Asif Alavi; Dianna Howard; Harlan W Waksal; John Ryan; David Eiznhamer; Sanjay K Aggarwal; Jonathan Ieyoub; Olivier Schueller; Laurie Green; Zhongming Yang; Heidi Krenz; Madan Jagasia; Bruce R Blazar; Steven Pavletic
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.